Amgen Inc

Protecting intellectual property is critical to our business since it allows for our investment in the research and development of new medicines, consequently, we are disappointed with today's decision, and we look forward to presenting our case to uphold the jury's verdict.

Not only does the rule raise serious freedom of speech concerns, it mandates an approach that fails to account for differences among insurance, treatments and patients themselves, by requiring disclosure of list price, most importantly, it does not answer the fundamental question patients are asking: 'What will I have to pay for my medicine?'.